Lyell Immunopharma reports Q4/FY2021 net loss $250.2M; cash $898M; two INDs cleared

Lyell Immunopharma, Inc.

Net loss $250.2M in FY2021 vs $204.5M in 2020; non-GAAP net loss $147.9M.
R&D expense $138.7M in FY2021, down from $182.2M; G&A expense $89.1M vs $46.9M.
Cash, cash equivalents and marketable securities $898M as of Dec 31, 2021.
FDA cleared INDs for LYL797 (CAR T targeting ROR1) and LYL132 (TCR targeting NY-ESO-1); initial data from LYL797 trial expected in 2023.
LYL845 TIL therapy IND on track for H2 2022; LYL331 IND (GSK collaboration) delayed to late 2022/early 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.